June 19, 2014
Eisai announced on June 17 that its antiepileptic treatment Fycompa (perampanel), which the company positions as its next mainstay product, has met its primary endpoints in a PIII clinical study in patients with primary generalized tonic-clonic (PGTC) seizures. The details...read more